Qatar Genomics Market Size, Growth, and Trends Forecast 2026-2034

Market Overview

The Qatar genomics market size was valued at USD 87.88 Million in 2025 and is projected to reach USD 248.43 Million by 2034, growing at a compound annual growth rate of 12.24% from 2026-2034. National initiatives advance genetic research and sequencing to support personalized healthcare solutions tailored for local populations, focusing on hereditary conditions and integrating precision approaches into clinical practice for improved outcomes.

How AI is Reshaping the Future of Qatar Genomics Market

• Qatar Genome Programme has sequenced over 45,000 local genomes, giving AI tools rich data to spot disease risks unique to the population.

• Qatar Precision Health Institute pairs AI with pharmacogenomics so doctors can match drugs to genes and cut hospital stays for many patients.

• Hamad Medical Corporation now uses AI to speed up genomic analysis, linking complex DNA results to symptoms for faster, more accurate diagnoses.

• Sidra Medicine applies AI-driven long-read sequencing to rare diseases, joining global consortia that speed diagnosis for children across the region.

• Government-backed Qai and UK-Qatar AI healthcare grants pour fresh funding into genomics tools that turn big data into everyday clinical decisions.

Grab a sample PDF of this report: https://www.imarcgroup.com/qatar-genomics-market/requestsample

Market Growth Factors

The Qatar genomics market is advancing rapidly as national initiatives prioritize precision medicine and population health. Growing investments in large-scale sequencing projects and biobank infrastructure are expanding research capacity and clinical applications. Collaboration between government entities, academic institutions, and international partners is accelerating the adoption of genomic technologies across healthcare systems, supporting earlier disease detection and more personalized treatment strategies tailored to the local population.

Increasing awareness of genetic conditions and the demand for preventive healthcare are major drivers shaping the market. Healthcare providers are integrating genomic testing into routine diagnostics for hereditary disorders and oncology, while public health programs emphasize screening and risk assessment. Supportive regulatory frameworks and ethical guidelines encourage responsible data use, fostering trust and wider acceptance of genomics-based solutions among clinicians and patients throughout Qatar.

Technological progress in next-generation sequencing, bioinformatics, and data analytics is further propelling market growth. Local research centers are building specialized expertise and computational resources to handle complex genomic datasets efficiently. These developments enable faster interpretation of results and seamless integration into electronic health records, ultimately improving clinical decision-making and strengthening Qatar’s position as a regional leader in genomic medicine and innovation.

Market Segmentation

Component Insights:

• Products

  • Instruments and Software

  • Consumables and Reagents

• Services

  • Core Genomics Services

  • NGS-Based Services

  • Biomarker Translation Services

  • Computational Services

  • Others

Technology Insights:

• Sequencing

• Microarray

• Polymerase Chain Reaction

• Nucleic Acid Extraction and Purification

• Others

Application Insights:

• Functional Genomics

• Epigenomics

• Biomarkers Discovery

• Pathway Analysis

• Others

End User Insights:

• Research Centers

• Hospitals and Clinics

• Pharmaceutical and Biotechnology Companies

• Others

Regional Insights:

• Ad Dawhah

• Al Rayyan

• Al Wakrah

• Others

Recent Developement & News

• August 2026: Qatar Precision Health Institute partners with Qatar National Library to open-source Genome Heroes educational materials globally via the Manara repository, providing free access to genetics and precision medicine resources for learners aged 6–14, including bilingual toolkits and an interactive mobile game.

• July 2026: Hamad Medical Corporation launches in-house Clinical Whole Exome Sequencing for the first time, alongside new pharmacogenomics and thrombophilia testing services, supporting personalized diagnosis within its Genetic Diagnostics Laboratory that conducts approximately 153,000 genetic tests annually.

• July 2026: Sidra Medicine administers Qatar’s first Itvisma one-time gene replacement therapy for spinal muscular atrophy to a 13-year-old patient, becoming the third country worldwide to deliver this advanced precision treatment for rare genetic disease.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302